CliffBio
small molecule

FOLOTYN

PRALATREXATE

Loss of exclusivity—loss of exclusivity
CompanyAcrotech Biopharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameFOLOTYN
Active ingredientPRALATREXATE
Strength20MG/ML (20MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalSeptember 2009
Marketing statusRX

More from Acrotech Biopharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

FOLOTYN patent cliff — loss of exclusivity — | CliffBio